Mer­ck winds down TIG­IT, LAG-3 pro­grams meant to tem­per Keytru­da ero­sion

Af­ter mul­ti­ple clin­i­cal fail­ures, it’s fi­nal­ly the end of the road for Mer­ck’s TIG­IT pro­gram.

The com­pa­ny is drop­ping de­vel­op­ment of its an­ti-TIG­IT can­di­date vi­bostolimab …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER